Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy
Open Access
- 28 December 2016
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 4 (4), 310-319
- https://doi.org/10.14218/jcth.2016.00027
Abstract
Hepatitis C virus (HCV) infection remains a significant medical concern in the United States and around the world. It is still one of the leading causes of chronic liver disease, and, for more than 20 years, there has been little progress in the treatment of HCV infection. The advent of direct-acting antivirals (DAAs) initiated the era of high efficacy and well-tolerated medications with high cure rates. The efficacy of these medications has prompted many professional societies around the world to update their treatment guidelines to include DAAs as first-line treatment. Guidelines by the American Association for the Study of Liver Disease/Infectious Disease Society of America, World Health Organization, Asian-Pacific Association for the Study of Liver and the European Association for the Study of Liver have all incorporated DAAs into their treatment guidelines. Despite the promising data supporting these medications, however, their cost represents a limiting factor to their use, even though studies have shown DAAs to be cost-effective. In addition to the expense of these medications and limited resources, there are many barriers preventing patients from receiving this potentially life-saving treatment. In order to overcome these barriers, these issues need to be recognized and addressed.Keywords
This publication has 36 references indexed in Scilit:
- A path to eradication of hepatitis C in low- and middle-income countriesAntiviral Research, 2015
- Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"Clinical Infectious Diseases, 2015
- Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infectionAlimentary Pharmacology & Therapeutics, 2015
- Estimates on HCV disease burden worldwide – filling the gapsJournal of Viral Hepatitis, 2015
- Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010Annals of Internal Medicine, 2014
- Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing CountriesClinical Infectious Diseases, 2014
- Indications for Testing Among Reported Cases of HCV Infection From Enhanced Hepatitis Surveillance Sites in the United States, 2004–2010American Journal of Public Health, 2013
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceJournal of Hepatology, 2013
- Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008Journal of Hepatology, 2011
- Evolving epidemiology of hepatitis C virusClinical Microbiology & Infection, 2011